Navigation Links
Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds

d-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with the possibility that the FDA declines to schedule an advisory panel meeting to review our NDA; the FDA refuses to approve our NDA; because our Phase 3 clinical trial known as the SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial failed to meet its primary endpoint, the FDA may require additional data, analysis or studies before the NDA is approved by the FDA; the outcome of any discussions with the FDA; the initiation, timing, design, enrollment and cost of clinical trials; unexpected delays in clinical trials and preparation of materials for submission to the FDA as part of our NDA filing; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to obtain future financing and fund the preparation of our NDA filing and the product development of our pipeline; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2006 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
3. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
4. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:12/24/2014)... LONDON , December 24, 2014 ... to grow at an average rate of 8.1%. The ... volume. Hip, knee and spine surgeries are the common ... economies they have a lower penetration. Increased number of ... of composites. Non-metallic orthopedic devices have gained popularity in ...
(Date:12/24/2014)... Dec. 23, 2014 Echo Therapeutics, Inc. ... company focused on skin permeation, continuous glucose monitoring ... W. Hollander has been appointed Chief Executive ... more than 20 years of experience in the ... most recently served as Vice President, Business Development, ...
(Date:12/24/2014)... SAN DIEGO , Dec. 23, 2014 ResMed ... a significant patent infringement action against Chinese medical device manufacturer ... Commission (ITC) ruled today that BMC,s masks listed below infringe ... advertising, or selling these masks in the United ... , iVolve N2 nasal mask , Willow nasal pillows ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... a division of Wyeth (NYSE: WYE ), ... which showed that bazedoxifene/conjugated,estrogens reduced the number and ... up to 80 percent, when compared with placebo. ... Annual Meeting,also showed that bazedoxifene/conjugated estrogens improved symptoms ...
... 4 A new scientific,review released today by ... evidence of benefit is lacking for many common ... dietary supplement,ingredients, a common surgical procedure, and injected ... chondroitin, over-the-counter,dietary supplement ingredients that are used widely ...
Cached Medicine Technology:Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 2Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 3Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 4Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee 2
(Date:12/25/2014)... (PRWEB) December 25, 2014 Plugin creators ... ProFire 5k. A fully customizable business presentation tool made ... “Adding the ProFire 5k business tool, users can now ... Austin, CEO of Pixel Film Studios. “ProFire 5k gives ... style to add professionalism to a presentation” , Pixel ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 Each ... visits and 2 million hospital admissions across the nation ... Prevention ). The CDC’s National Hospital Ambulatory Medical ... through a survey conducted in 2010. They estimated that ... visits that resulted in a primary diagnosis of broken ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping ... items. During the holiday season, AlignLife looks forward to their ... says Dr. Sara Mahalko-Leonhardt, owner of AlignLife. "It brings our ... that we are able to give kids toys for Christmas ... for the generosity of our patients." , The 70 toys ...
(Date:12/24/2014)... finds applications in a large number of fields of ... and research for metabolic and genetic disorders. It is ... techniques for the discovery and development of cancer biomarkers. ... growing worldwide. In 2012, there were 14.1 million new ... people living with cancer (within five years of diagnosis) ...
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and retailer, has ... All these items are brand new; they are made by ... with the new range of high quality prom gowns. A ... designs are made according to the latest trends. For years, ... from the company is handpicked by skilled tailors. , In ...
Breaking Medicine News(10 mins):Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... RICHMOND, Va., Feb. 6 A new statewide ... using,tobacco settlement and tobacco tax revenue for programs ... smokers quit., The poll of 500 Virginia ... American Heart Association, American Lung Association and,the Campaign ...
... German . , Scientists from the University of Bonn ... than 100 million years ago. They want to find out how ... In actual fact such gigantic animals should not have existed. The ... ,Proceedings of the Royal Society B,. , Take 200 milligrammes of ...
... large, multi-institutional study comparing the accuracy of positron emission ... of lung nodules found that PET was far more ... malignant. , CT and PET have been widely used ... malignant, said James W. Fletcher, professor of radiology at ...
... Feb. 6 As it prepares to mark,its ... solutions,to the healthcare industry, Sentillion, the company that ... In Q4, Sentillion,added 10 new customers in North ... licenses and brought 17,000 additional users,live across its ...
... Healthy Lifestyles at N.C. ... Department of Transportation, RALEIGH, ... building healthy lifestyles in North Carolina by making a,$1.5 million ... North Carolina State Health Plan, will fund for three years,a ...
... ... markets -, WOONSOCKET, R.I., Feb. 6 If you have ever been ... or other vehicular,emergency, you are probably familiar with the feeling of relief that ... has,provided that help and relief to more than a million drivers in need ...
Cached Medicine News:Health News:New Poll Shows Virginia Voters Overwhelmingly Favor Funding for Tobacco Prevention 2Health News:New Poll Shows Virginia Voters Overwhelmingly Favor Funding for Tobacco Prevention 3Health News:Bonn scientists simulate dinosaur digestion in the lab 2Health News:Bonn scientists simulate dinosaur digestion in the lab 3Health News:PET outperforms CT in characterization of lung nodules 2Health News:Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses 2Health News:Sentillion Announces Strong Q4 Performance; Signs 10 New Customers; Sells 95,800 Licenses 3Health News:AstraZeneca Gives $1.5 million to Support North Carolina Worksite Wellness Project 2Health News:AstraZeneca Gives $1.5 million to Support North Carolina Worksite Wellness Project 3Health News:CVS Samaritan Van Program Celebrates 30 Years of Helping Motorists on the Nation's Highways 2Health News:CVS Samaritan Van Program Celebrates 30 Years of Helping Motorists on the Nation's Highways 3Health News:CVS Samaritan Van Program Celebrates 30 Years of Helping Motorists on the Nation's Highways 4
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: